Cegedim Dendrite CRM solution moving to BlackBerry

Share this article:

Cegedim Dendrite customers will soon be able to access Mobile Intelligence, the company's flagship CRM platform from their BlackBerrys. The rollout is expected to launch sometime in the late third quarter and early fourth quarter.

“We've gotten a lot of questions from our customers over the last year about how they could use a BlackBerry and how we could leverage this platform. For many of our customers the BlackBerry has become a standard issue for their commercial teams,” said Mark Fleischer, SVP & general manager, North American CRM.

At a company conference in New York City, Fleischer said that the first phase of the BlackBerry rollout will be an online application. Using the BlackBerry data network, end users will be able to access Mobile Intelligence in order to manage customers, appointments, affiliations, and call reporting.

“A lot of commercial team members [reps and account managers], especially the ones that may be involved in account-based selling don't like to carry a big bag on their shoulders, they prefer the ability to move around at their account locations and connect with people. They can do that more easily with the BlackBerry,” said Fleischer.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...